Patricia M LoRusso
Yale University Cancer Center LAO
6
6
1
N/A
0
14
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+13 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (6)
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Vincent Chung
City of Hope Medical Center
Shared therapeutic areas:
Worked with same sponsors:
Flemming Forsberg, phD
Thomas Jefferson University
Shared therapeutic areas:
Worked with same sponsors:
Sriram Yennu
M.D. Anderson Cancer Center
Shared therapeutic areas:
Worked with same sponsors:
David Hui
M.D. Anderson Cancer Center
Shared therapeutic areas:
Worked with same sponsors:
Aung Naing, Md
M.D. Anderson Cancer Center
Shared therapeutic areas:
Worked with same sponsors:
David Hui, MD
M.D. Anderson Cancer Center
Shared therapeutic areas:
Worked with same sponsors:
Michael Schweizer
Fred Hutch/University of Washington Cancer Consortium
Shared therapeutic areas:
Worked with same sponsors:
Steven A Rosenberg, M.D.
National Cancer Institute (NCI)
Shared therapeutic areas:
Worked with same sponsors:
Glenn Lesser, MD
Wake Forest University Health Sciences
Shared therapeutic areas:
Worked with same sponsors:
Lorenzo Cohen
M.D. Anderson Cancer Center
Shared therapeutic areas:
Worked with same sponsors:
Publications (0)
No publications found for this investigator.
Clinical Trials (6)
Showing 6 of 6 trials
Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors
Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and Lymphomas
Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors
Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations
Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer
Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery
All 6 trials loaded